<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558034</url>
  </required_header>
  <id_info>
    <org_study_id>NUR20-0124CRYO</org_study_id>
    <nct_id>NCT04558034</nct_id>
  </id_info>
  <brief_title>The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer</brief_title>
  <official_title>The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parkview Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parkview Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy of cryotherapy to prevent paclitaxel-induced&#xD;
      peripheral neuropathy and nail changes in women with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with breast cancer receiving paclitaxel will complete the Brief Pain Inventory(BPI),&#xD;
      Neuropathic Pain Syndrome Inventory (NPSI)while a member of the research team will conduct an&#xD;
      assessment of their nails. Once complete, cryotherapy will be administered 15 minutes prior&#xD;
      to the paclitaxel infusion, continuously during and then 15 minutes after completion of the&#xD;
      paclitaxel for a total of 90 minutes. Cyrotherapy will be delivered using Elasto-gel mitts&#xD;
      and Rapid relief slippers. These items will be changed 45min after initiation to ensure&#xD;
      coldness.&#xD;
&#xD;
      There will be two arms of the study. One arm will include subjects who will wear one&#xD;
      slipper/one mitt on their foot/hand while the other foot/hand will serve as a control. The&#xD;
      other arm will include subjects who will have cryotherapy to both hands and feet. . This&#xD;
      process will be repeated for a total of 12 times in conjunction with 12 doses of paclitaxel.&#xD;
      At time point 13, during a routine visit to their oncologist, the subjects nails will be&#xD;
      reassessed along with completion of the BPI and NPSIA total of 25 subjects will be enrolled&#xD;
      in each arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator retired before study completed.&#xD;
  </why_stopped>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Actual">February 3, 2021</completion_date>
  <primary_completion_date type="Actual">February 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are 2 arms to the study.The Elasto-gel mitt and Rapid Relief slipper will be placed either on one hand/foot or both based on the patient's medical oncologist. All subjects will have a standardized onset/duration of therapy which includes the following :&#xD;
15 minutes prior to the paclitaxel infusion,&#xD;
Continuously during the paclitaxel infusion,&#xD;
15 minutes after completion of paclitaxel for a total of 90 minutes.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbness,tingling,pain ,nail toxicities</measure>
    <time_frame>13 weeks</time_frame>
    <description>absence of numbness and tingling in the treated hands/feet&#xD;
If there is an absence of pain in the treated hands/feet&#xD;
If there is an absence of nail changes in the treated hands/feet</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Cryotherapy Effect</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Nail Toxicity</condition>
  <arm_group>
    <arm_group_label>Interventioncryotherapy/control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will have one mitt/one slipper and serve as their own control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will have two mitts/slippers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cryotherapy</intervention_name>
    <description>cryotherapy will be delivered</description>
    <arm_group_label>Interventioncryotherapy/control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females 18 or older&#xD;
&#xD;
          -  Histologically confirmed diagnosis of breast cancer&#xD;
&#xD;
          -  Receiving neo-adjuvant or adjuvant dose-dense anthracycline (AC) plus taxane-based&#xD;
             chemotherapy or paclitaxel in combination with trastuzumab and pertuzumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior taxane therapy&#xD;
&#xD;
          -  Prior oxaliplatin therapy&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  History of peripheral neuropathy, i.e., Buerger's disease&#xD;
&#xD;
          -  History of diabetes mellitus&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy from other conditions, e.g., Raynaud's disease,&#xD;
             Guillain-Barre, Miller Fisher Syndrome&#xD;
&#xD;
          -  Hand, nail or foot conditions, e.g., hand/foot syndrome, arthritis, hammer toe, carpal&#xD;
             tunnel, bunions, deformities&#xD;
&#xD;
          -  Alcohol abuse (history/current)&#xD;
&#xD;
          -  Current medication usage of opioids, anti-depressants, anti-convulsants, glutamines,&#xD;
             vitamin B12&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle R Payne, MSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkview Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkview Cancer Institute</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alessandrini A, Starace M, Cer√® G, Brandi N, Piraccini BM. Management and Outcome of Taxane-Induced Nail Side Effects: Experience of 79 Patients from a Single Centre. Skin Appendage Disord. 2019 Aug;5(5):276-282. doi: 10.1159/000497824. Epub 2019 Mar 22.</citation>
    <PMID>31559250</PMID>
  </reference>
  <reference>
    <citation>Autissier E. Chemotherapy-Induced Peripheral Neuropathy: Association With Increased Risk of Falls and Injuries. Clin J Oncol Nurs. 2019 Aug 1;23(4):405-410. doi: 10.1188/19.CJON.405-410. Review.</citation>
    <PMID>31322611</PMID>
  </reference>
  <reference>
    <citation>Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014 Mar 19;6:135-47. doi: 10.2147/CMAR.S44261. eCollection 2014. Review.</citation>
    <PMID>24672257</PMID>
  </reference>
  <reference>
    <citation>Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162.</citation>
    <PMID>28954297</PMID>
  </reference>
  <reference>
    <citation>Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004 Apr;108(3):248-257. doi: 10.1016/j.pain.2003.12.024.</citation>
    <PMID>15030944</PMID>
  </reference>
  <reference>
    <citation>Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014 Jul 16;3:366. doi: 10.1186/2193-1801-3-366. eCollection 2014.</citation>
    <PMID>25089251</PMID>
  </reference>
  <reference>
    <citation>Can G, Aydiner A, Cavdar I. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs. 2012 Jul;16(3):270-5. doi: 10.1016/j.ejon.2011.06.007. Epub 2011 Jul 23.</citation>
    <PMID>21784705</PMID>
  </reference>
  <reference>
    <citation>Capriotti K, Capriotti JA, Lessin S, Wu S, Goldfarb S, Belum VR, Lacouture ME. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol. 2015 Sep;173(3):842-5. doi: 10.1111/bjd.13743. Epub 2015 Jul 29. Review.</citation>
    <PMID>25704465</PMID>
  </reference>
  <reference>
    <citation>Chan YN, Jheng YW, Wang PJ, Chen CY, Lin MW, Wang YJ. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer. Clin J Oncol Nurs. 2019 Oct 1;23(5):494-501. doi: 10.1188/19.CJON.494-501.</citation>
    <PMID>31538967</PMID>
  </reference>
  <reference>
    <citation>Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002 Oct;29(5 Suppl 15):11-20. Review.</citation>
    <PMID>12422304</PMID>
  </reference>
  <reference>
    <citation>Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003 Oct;26(5):435-6.</citation>
    <PMID>14528066</PMID>
  </reference>
  <reference>
    <citation>Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994 Mar;23(2):129-38. Review.</citation>
    <PMID>8080219</PMID>
  </reference>
  <reference>
    <citation>Cioroiu C, Weimer LH. Update on Chemotherapy-Induced Peripheral Neuropathy. Curr Neurol Neurosci Rep. 2017 Jun;17(6):47. doi: 10.1007/s11910-017-0757-7. Review.</citation>
    <PMID>28421360</PMID>
  </reference>
  <reference>
    <citation>Cunningham D, Gilchrist NL, Forrest GJ, Soukop M. Onycholysis associated with cytotoxic drugs. Br Med J (Clin Res Ed). 1985 Mar 2;290(6469):675-6.</citation>
    <PMID>2578850</PMID>
  </reference>
  <reference>
    <citation>Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer. 1982 Nov 1;50(9):1913-8.</citation>
    <PMID>7116316</PMID>
  </reference>
  <reference>
    <citation>De Giorgi U, Rosti G, Monti M, Frassineti GL, Marangolo M. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL). Ann Oncol. 2003 Oct;14(10):1588-9.</citation>
    <PMID>14504063</PMID>
  </reference>
  <reference>
    <citation>Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, Couette B, Busserolles J, Courteix C, Noel J, Lazdunski M, Eschalier A, Authier N, Bourinet E. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011 May;3(5):266-78. doi: 10.1002/emmm.201100134. Epub 2011 Mar 24.</citation>
    <PMID>21438154</PMID>
  </reference>
  <reference>
    <citation>Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013 Nov;142(1):109-18. doi: 10.1007/s10549-013-2728-2. Epub 2013 Oct 17.</citation>
    <PMID>24132874</PMID>
  </reference>
  <reference>
    <citation>Elasto-Gel(2019).Elasto-Gel.Retrieved on December 1,2019 from https://www.elastogels.com/product/elasto-gel-hot-cold-therapy-mitten/</citation>
  </reference>
  <reference>
    <citation>Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997 Oct;35(1):47-53.</citation>
    <PMID>9266440</PMID>
  </reference>
  <reference>
    <citation>Flory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB. Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother. 1999 May;33(5):584-6.</citation>
    <PMID>10369623</PMID>
  </reference>
  <reference>
    <citation>Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009 Sep;15(3):143-55. doi: 10.1177/1078155208100450. Epub 2009 Jan 26. Review.</citation>
    <PMID>19171552</PMID>
  </reference>
  <reference>
    <citation>Griffiths C, Kwon N, Beaumont JL, Paice JA. Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Support Care Cancer. 2018 Oct;26(10):3461-3469. doi: 10.1007/s00520-018-4199-9. Epub 2018 Apr 21.</citation>
    <PMID>29681015</PMID>
  </reference>
  <reference>
    <citation>Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012 Sep;14 Suppl 4:iv45-54. doi: 10.1093/neuonc/nos203. Review.</citation>
    <PMID>23095830</PMID>
  </reference>
  <reference>
    <citation>Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. J Natl Cancer Inst. 2018 Feb 1;110(2):141-148. doi: 10.1093/jnci/djx178.</citation>
    <PMID>29924336</PMID>
  </reference>
  <reference>
    <citation>Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15-49. Review.</citation>
    <PMID>16473643</PMID>
  </reference>
  <reference>
    <citation>Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. Epub 2014 Apr 14. Review.</citation>
    <PMID>24733808</PMID>
  </reference>
  <reference>
    <citation>Hoffman,K. (2014). Diagnosing and Treating Chemotherapy-Induced Nail Changes. Podiatry Today,27(2). Retrieved on December 16, 2019from https://www.podiatrytoday.com/diagnosing-and-treating-chemotherapy-induced-nail-changes</citation>
  </reference>
  <reference>
    <citation>Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer. 2000 May 15;88(10):2367-71. Review.</citation>
    <PMID>10820360</PMID>
  </reference>
  <reference>
    <citation>Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. Support Care Cancer. 2012 Sep;20(9):2017-24. doi: 10.1007/s00520-011-1308-4. Epub 2011 Nov 16.</citation>
    <PMID>22086405</PMID>
  </reference>
  <reference>
    <citation>LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013 Jul;37:231-9. doi: 10.1016/j.neuro.2013.05.008. Epub 2013 May 24.</citation>
    <PMID>23711742</PMID>
  </reference>
  <reference>
    <citation>Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 Apr 1;24(10):1633-42. Review.</citation>
    <PMID>16575015</PMID>
  </reference>
  <reference>
    <citation>Kadakia KC, Rozell SA, Butala AA, Loprinzi CL. Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage. 2014 Jun;47(6):1100-15. doi: 10.1016/j.jpainsymman.2013.07.014. Epub 2013 Nov 7. Review.</citation>
    <PMID>24210702</PMID>
  </reference>
  <reference>
    <citation>Kerckhove N, Collin A, Cond√© S, Chaleteix C, Pezet D, Balayssac D. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol. 2017 Feb 24;8:86. doi: 10.3389/fphar.2017.00086. eCollection 2017. Review.</citation>
    <PMID>28286483</PMID>
  </reference>
  <reference>
    <citation>Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016 Jul 1;73(7):860-6. doi: 10.1001/jamaneurol.2016.0383.</citation>
    <PMID>27183099</PMID>
  </reference>
  <reference>
    <citation>Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: a focused review. Indian J Palliat Care. 2011 May;17(2):108-15. doi: 10.4103/0973-1075.84531.</citation>
    <PMID>21976850</PMID>
  </reference>
  <reference>
    <citation>Lau CP, Hui P, Chan TC. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chin Med J (Engl). 2011 Aug;124(16):2559-60. Review.</citation>
    <PMID>21933605</PMID>
  </reference>
  <reference>
    <citation>McCarthy AL, Shaban RZ, Gillespie K, Vick J. Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer. 2014 May;22(5):1375-83. doi: 10.1007/s00520-013-2095-x. Epub 2013 Dec 22.</citation>
    <PMID>24362908</PMID>
  </reference>
  <reference>
    <citation>Memorial Sloan Kettering Cancer Center (2017) Nail changes during treatment with Taxane-based chemotherapy Retrieved December17,2019 from https://www.mskcc.org/pdf/cancer-care/patient-education/nail-changes-during-treatment-taxanes</citation>
  </reference>
  <reference>
    <citation>Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014 Aug;40(7):872-82. doi: 10.1016/j.ctrv.2014.04.004. Epub 2014 Apr 18. Review.</citation>
    <PMID>24830939</PMID>
  </reference>
  <reference>
    <citation>Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003 Feb;14(2):333-7.</citation>
    <PMID>12562663</PMID>
  </reference>
  <reference>
    <citation>Monjazeb S, Wilson J. Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management. Skin Therapy Lett. 2017 Sep;22(5):5-7. Review.</citation>
    <PMID>28888217</PMID>
  </reference>
  <reference>
    <citation>Nicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. Australas J Dermatol. 2002 Nov;43(4):293-6. Review.</citation>
    <PMID>12423438</PMID>
  </reference>
  <reference>
    <citation>Oncology Nursing Society.(2017). Cutaneous reactions. Retrieved on December 11, 2019 from https://www.ons.org/pep/skin-reactions</citation>
  </reference>
  <reference>
    <citation>Oncology Nursing Society.(2019). Peripheral neuropathy . Retrieved on December 11, 2019 from https://www.ons.org/pep/peripheral-neuropathy</citation>
  </reference>
  <reference>
    <citation>Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37. doi: 10.3322/caac.21204. Review.</citation>
    <PMID>24590861</PMID>
  </reference>
  <reference>
    <citation>Paul LJ, Cohen PR. Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. J Drugs Dermatol. 2012 Feb;11(2):262-8. Review.</citation>
    <PMID>22270214</PMID>
  </reference>
  <reference>
    <citation>Peyton L, Fischer-Cartlidge E. Extremity Cooling: A Synthesis of Cryotherapy Interventions to Reduce Peripheral Neuropathy and Nail Changes From Taxane-Based Chemotherapy. Clin J Oncol Nurs. 2019 Oct 1;23(5):522-528. doi: 10.1188/19.CJON.522-528. Review.</citation>
    <PMID>31538978</PMID>
  </reference>
  <reference>
    <citation>Poncelet AN. An algorithm for the evaluation of peripheral neuropathy. Am Fam Physician. 1998 Feb 15;57(4):755-64. Review.</citation>
    <PMID>9490998</PMID>
  </reference>
  <reference>
    <citation>Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002 Jan;249(1):9-17. Review.</citation>
    <PMID>11954874</PMID>
  </reference>
  <reference>
    <citation>Rapid Aid. (2020). Cold Gel Slippers. Retrieved on March 2,2020 from http://rapidaid.com/product/hot-cold-gel-slippers/</citation>
  </reference>
  <reference>
    <citation>Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, Baran R. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015 Apr;16(4):e181-9. doi: 10.1016/S1470-2045(14)71133-7. Review.</citation>
    <PMID>25846098</PMID>
  </reference>
  <reference>
    <citation>Ross M, Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia . Clin J Oncol Nurs. 2017 Apr 1;21(2):226-233. doi: 10.1188/17.CJON.226-233.</citation>
    <PMID>28315539</PMID>
  </reference>
  <reference>
    <citation>Sanofi (2019).Taxotere prescribing information. Retreived on December 11, 2019 from http://products.sanofi.us/taxotere/Taxotere.html</citation>
  </reference>
  <reference>
    <citation>Sato J, Mori M, Nihei S, Kumagai M, Takeuchi S, Kashiwaba M, Kudo K. The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. J Pharm Health Care Sci. 2016 Nov 15;2:33. eCollection 2016.</citation>
    <PMID>27891244</PMID>
  </reference>
  <reference>
    <citation>Scott√© F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005 Jul 1;23(19):4424-9.</citation>
    <PMID>15994152</PMID>
  </reference>
  <reference>
    <citation>Scott√© F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Tourani JM, Andrieu JM, Oudard S. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008 Apr 1;112(7):1625-31. doi: 10.1002/cncr.23333.</citation>
    <PMID>18286527</PMID>
  </reference>
  <reference>
    <citation>Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23. Review.</citation>
    <PMID>25261162</PMID>
  </reference>
  <reference>
    <citation>Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri MD, Veronesi A, Gatti A. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading? J Clin Oncol. 2002 Nov 1;20(21):4404-5; author reply 4405.</citation>
    <PMID>12409345</PMID>
  </reference>
  <reference>
    <citation>Starobova, H., Vetter, I. (2017). Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in Molecular Neuroscience, 10, 174. doi:10.3389/fnmol.2017.00174 Retrieved June 25, 2018, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450696/</citation>
  </reference>
  <reference>
    <citation>Sundar R, Bandla A, Tan SS, Liao LD, Kumarakulasinghe NB, Jeyasekharan AD, Ow SG, Ho J, Tan DS, Lim JS, Vijayan J, Therimadasamy AK, Hairom Z, Ang E, Ang S, Thakor NV, Lee SC, Wilder-Smith EP. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Front Oncol. 2017 Jan 10;6:274. doi: 10.3389/fonc.2016.00274. eCollection 2016.</citation>
    <PMID>28119855</PMID>
  </reference>
  <reference>
    <citation>Swenson KK, Bell EM, Nissen J. Nail toxicity associated with paclitaxel treatment for ovarian cancer. Oncol Nurs Forum. 2013 Jan;40(1):17-9. doi: 10.1188/13.ONF.17-19.</citation>
    <PMID>23269765</PMID>
  </reference>
  <reference>
    <citation>Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin J Oncol Nurs. 2013 Apr;17(2):138-44. doi: 10.1188/13.CJON.138-144.</citation>
    <PMID>23538249</PMID>
  </reference>
  <reference>
    <citation>U.S Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Retrieved on December 12, 2019 from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.</citation>
  </reference>
  <reference>
    <citation>Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007 Jun;11(3):361-76. Review.</citation>
    <PMID>17623621</PMID>
  </reference>
  <reference>
    <citation>Wildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS, Stark S. Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2015 Jan;6(1):70-83. doi: 10.1016/j.jgo.2014.10.003. Epub 2014 Oct 30. Review.</citation>
    <PMID>25454770</PMID>
  </reference>
  <reference>
    <citation>Wilkinson,M., Cocilovo,C., &amp; Schar,M. (2016) Reduction of paclitaxel neuropathy with cryotherapy.Journal of Clinical Oncology.34(suppl 3S;abst 124) retrieved on December 2,2019 from https://meetinglibrary.asco.org/record/119151/abstract</citation>
  </reference>
  <reference>
    <citation>Willis, W.D (2000). The nervous system. In R.M. Berne &amp; M.N. Levy (Eds.). Principles of physiology (pp. 68-94). St. Louis: Mosby.</citation>
  </reference>
  <reference>
    <citation>Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2017 Aug 10;35(23):2604-2612. doi: 10.1200/JCO.2016.71.3552. Epub 2017 Jun 6.</citation>
    <PMID>28586243</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Parkview Health</investigator_affiliation>
    <investigator_full_name>Danielle Payne</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The following will be shared: Individual participant data that underlie the results reported in the planned article after deidentification including text,tables,figures, appendices</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately following publication and no end date</ipd_time_frame>
    <ipd_access_criteria>Data will be available to anyone who wishes to access the data for any purpose by contacting nancy.ehmke@parkview.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

